STAAR Surgical Company (STAA) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

STAA Stock Forecast


STAAR Surgical Company stock forecast is as follows: an average price target of $54.58 (represents a 87.30% upside from STAA’s last price of $29.14) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.

STAA Price Target


The average price target for STAAR Surgical Company (STAA) is $54.58 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $85.00 to $45.03. This represents a potential 87.30% upside from STAA's last price of $29.14.

STAA Analyst Ratings


Buy

According to 13 Wall Street analysts, STAAR Surgical Company's rating consensus is 'Buy'. The analyst rating breakdown for STAA stock is 0 'Strong Buy' (0.00%), 11 'Buy' (84.62%), 1 'Hold' (7.69%), 1 'Sell' (7.69%), and 0 'Strong Sell' (0.00%).

STAAR Surgical Company Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 11, 2024Ryan ZimmermanBTIG$46.00$38.0720.83%57.86%
Apr 09, 2024Raj DenhoyJefferies$60.00$50.5918.61%105.90%
Apr 08, 2024John YoungCanaccord Genuity$46.00$48.68-5.51%57.86%
Apr 04, 2024Margaret KaczorWilliam Blair$45.03$45.54-1.12%54.53%
Jan 11, 2023Stephens StephensStephens$85.00$68.5623.98%191.70%
Sep 23, 2022-Truist Financial$48.00$71.93-33.27%64.72%
Sep 23, 2022-RBC Capital$52.00$73.19-28.95%78.45%
Jul 19, 2022-Truist Financial$54.00$74.65-27.66%85.31%
Apr 26, 2022-Canaccord Genuity$89.00$59.0250.80%205.42%
Mar 23, 2022Michael CiarmoliTruist Financial$58.00$71.96-19.40%99.04%
Row per page
Go to

The latest STAAR Surgical Company stock forecast, released on Jun 11, 2024 by Ryan Zimmerman from BTIG, set a price target of $46.00, which represents a 20.83% increase from the stock price at the time of the forecast ($38.07), and a 57.86% increase from STAA last price ($29.14).

STAAR Surgical Company Price Target by Period


1M3M12M
# Anlaysts--4
Avg Price Target--$49.26
Last Closing Price$29.14$29.14$29.14
Upside/Downside-100.00%-100.00%69.05%

In the current month, the average price target of STAAR Surgical Company stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to STAAR Surgical Company's last price of $29.14. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jul 15, 2024Morgan Stanley-UnderweightDowngrade
Jun 11, 2024Piper SandlerBuyBuyHold
Apr 09, 2024JefferiesBuyBuyHold
Apr 08, 2024Canaccord GenuityHoldHoldHold
Apr 04, 2024William BlairMarket PerformOutperformUpgrade
Apr 04, 2024Stifel NicolausBuyBuyHold
Mar 11, 2024BarclaysUnderperformUnderperformHold
Sep 15, 2023NeedhamBuyBuyHold
Jun 07, 2023William Blair-Market PerformDowngrade
Dec 28, 2022OppenheimerOutperformOutperformHold
Row per page
Go to

STAAR Surgical Company's last stock rating was published by Morgan Stanley on Jul 15, 2024. The company Downgrade its STAA rating from "null" to "Underweight".

STAAR Surgical Company Financial Forecast


STAAR Surgical Company Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$76.27K$80.31M$92.31M$73.53M$64.04M$76.05M$81.10M$63.20M$59.00M$58.35M$62.37M$50.75M$38.88M$47.08M$35.19M$35.19M-$39.05M
Avg Forecast$137.69M$131.10M$124.83M$118.86M$88.37M$99.27M$110.32M$84.46M$77.83M$86.90M$95.22M$75.34M$75.94M$80.37M$92.51M$66.23M$64.12M$74.95M$80.12M$60.53M$59.49M$57.90M$52.59M$44.26M$44.28M$42.99M$35.75M$32.94M$38.43M$38.57M
High Forecast$143.67M$136.80M$130.26M$124.03M$92.21M$103.58M$115.12M$88.86M$79.86M$87.12M$95.22M$75.58M$79.24M$80.39M$96.53M$69.10M$66.91M$74.95M$80.12M$60.53M$59.49M$57.90M$52.59M$44.26M$44.28M$42.99M$35.75M$32.94M$38.43M$38.57M
Low Forecast$130.16M$123.93M$118.01M$112.36M$83.54M$93.84M$104.29M$80.24M$75.22M$86.68M$95.22M$75.09M$71.79M$80.35M$87.45M$62.60M$60.61M$74.95M$80.12M$60.53M$59.49M$57.90M$52.59M$44.26M$44.28M$42.99M$35.75M$32.94M$38.43M$38.57M
# Analysts2222111586446333222255551115881014
Surprise %------------0.00%1.00%1.00%1.11%1.00%1.01%1.01%1.04%0.99%1.01%1.19%1.15%0.88%1.10%0.98%1.07%-1.01%

STAAR Surgical Company's average Quarter revenue forecast for Mar 24 based on 4 analysts is $75.34M, with a low forecast of $75.09M, and a high forecast of $75.58M. STAA's average Quarter revenue forecast represents a 98672.49% increase compared to the company's last Quarter revenue of $76.27K (Dec 23).

STAAR Surgical Company EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts2222111586446333222255551115881014
EBITDA------------$10.40K$9.02M$8.60M$3.89M$-847.00K$16.92M$19.92M$14.03M$7.92M$8.28M$11.61M$7.11M$3.99M$6.15M$164.00K$-301.00K-$4.29M
Avg Forecast$16.92M$16.11M$15.34M$14.60M$10.86M$12.20M$13.55M$10.38M$9.56M$10.68M$11.70M$9.26M$9.33M$9.87M$11.36M$8.14M$8.75M$9.21M$9.84M$7.44M$7.31M$7.11M$6.46M$5.44M$5.44M$5.28M$4.39M$-895.93K$4.72M$4.74M
High Forecast$17.65M$16.81M$16.00M$15.24M$11.33M$12.73M$14.14M$10.92M$9.81M$10.70M$11.70M$9.29M$9.74M$9.88M$11.86M$8.49M$10.50M$9.21M$9.84M$7.44M$7.31M$7.11M$6.46M$5.44M$5.44M$5.28M$4.39M$-716.75K$4.72M$4.74M
Low Forecast$15.99M$15.23M$14.50M$13.80M$10.26M$11.53M$12.81M$9.86M$9.24M$10.65M$11.70M$9.23M$8.82M$9.87M$10.74M$7.69M$7.00M$9.21M$9.84M$7.44M$7.31M$7.11M$6.46M$5.44M$5.44M$5.28M$4.39M$-1.08M$4.72M$4.74M
Surprise %------------0.00%0.91%0.76%0.48%-0.10%1.84%2.02%1.89%1.08%1.16%1.80%1.31%0.73%1.16%0.04%0.34%-0.91%

4 analysts predict STAA's average Quarter EBITDA for Mar 24 to be $9.26M, with a high of $9.29M and a low of $9.23M. This is 88853.28% upper than STAAR Surgical Company's previous annual EBITDA (Dec 23) of $10.40K.

STAAR Surgical Company Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts2222111586446333222255551115881014
Net Income------------$7.76K$4.82M$6.06M$2.71M$6.10M$10.26M$13.04M$9.60M$4.92M$6.02M$8.57M$4.99M$6.38M$3.89M$-1.17M$-134.00K-$2.39M
Avg Forecast$5.47M$17.41M$20.89M$2.49M$7.46M$14.04M$18.46M$4.70M$-1.38M$8.94M$11.88M$82.52M$8.89M$8.82M$14.22M$75.02M$5.41M$9.96M$11.60M$68.20M$8.48M$8.30M$4.06M$53.91M$4.07M$4.32M$374.33K$-232.22K$3.49M$4.61M
High Forecast$5.78M$18.39M$22.07M$2.63M$7.88M$14.83M$19.50M$7.83M$-1.11M$9.15M$11.88M$99.03M$14.04M$9.32M$15.02M$90.02M$6.50M$9.96M$11.60M$81.84M$8.48M$8.30M$4.06M$64.70M$4.07M$4.32M$374.33K$-185.77K$3.49M$4.61M
Low Forecast$5.08M$16.17M$19.40M$2.31M$6.93M$13.04M$17.14M$1.88M$-1.52M$8.74M$11.88M$66.02M$6.08M$8.19M$13.21M$60.02M$4.33M$9.96M$11.60M$54.56M$8.48M$8.30M$4.06M$43.13M$4.07M$4.32M$374.33K$-278.66K$3.49M$4.61M
Surprise %------------0.00%0.55%0.43%0.04%1.13%1.03%1.12%0.14%0.58%0.73%2.11%0.09%1.57%0.90%-3.13%0.58%-0.52%

STAAR Surgical Company's average Quarter net income forecast for Mar 24 is $82.52M, with a range of $66.02M to $99.03M. STAA's average Quarter net income forecast represents a 1063887.24% increase compared to the company's last Quarter net income of $7.76K (Dec 23).

STAAR Surgical Company SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts2222111586446333222255551115881014
SG&A------------$50.32K$45.87M$62.13M$44.45M$39.03M$37.14M$38.22M$29.21M$28.54M$29.19M$30.29M$23.41M$19.07M$21.24M$18.17M$19.00M-$19.56M
Avg Forecast$69.76M$66.42M$63.25M$60.22M$44.77M$50.29M$55.89M$42.79M$39.43M$44.03M$48.24M$38.17M$38.48M$40.72M$46.87M$33.55M$31.39M$37.97M$40.59M$30.67M$30.14M$29.33M$26.64M$22.42M$22.43M$21.78M$18.11M$32.92M$19.47M$19.54M
High Forecast$72.79M$69.31M$66.00M$62.84M$46.72M$52.48M$58.32M$45.02M$40.46M$44.14M$48.24M$38.29M$40.15M$40.73M$48.91M$35.01M$37.67M$37.97M$40.59M$30.67M$30.14M$29.33M$26.64M$22.42M$22.43M$21.78M$18.11M$39.51M$19.47M$19.54M
Low Forecast$65.94M$62.79M$59.79M$56.93M$42.32M$47.54M$52.84M$40.65M$38.11M$43.92M$48.24M$38.05M$36.37M$40.71M$44.30M$31.72M$25.11M$37.97M$40.59M$30.67M$30.14M$29.33M$26.64M$22.42M$22.43M$21.78M$18.11M$26.34M$19.47M$19.54M
Surprise %------------0.00%1.13%1.33%1.32%1.24%0.98%0.94%0.95%0.95%1.00%1.14%1.04%0.85%0.98%1.00%0.58%-1.00%

STAAR Surgical Company's average Quarter SG&A projection for Mar 24 is $38.17M, based on 4 Wall Street analysts, with a range of $38.05M to $38.29M. The forecast indicates a 75753.03% rise compared to STAA last annual SG&A of $50.32K (Dec 23).

STAAR Surgical Company EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts2222111586446333222255551115881014
EPS------------$0.16$0.10$0.13$0.06$0.13$0.21$0.27$0.20$0.10$0.13$0.18$0.11$0.14$0.08$-0.03$-0.00-$0.05
Avg Forecast$0.11$0.35$0.42$0.05$0.15$0.28$0.37$0.09$-0.03$0.18$0.24$0.06$0.18$0.18$0.29$0.07$0.13$0.20$0.23$0.15$0.17$0.17$0.08$0.03$0.08$0.09$0.01$0.03$0.07$0.09
High Forecast$0.12$0.37$0.44$0.05$0.16$0.30$0.39$0.16$-0.02$0.18$0.24$0.06$0.28$0.19$0.30$0.08$0.14$0.20$0.23$0.15$0.17$0.17$0.08$0.03$0.08$0.09$0.01$0.03$0.07$0.09
Low Forecast$0.10$0.33$0.39$0.05$0.14$0.26$0.34$0.04$-0.03$0.18$0.24$0.06$0.12$0.16$0.27$0.07$0.13$0.20$0.23$0.15$0.17$0.17$0.08$0.03$0.08$0.09$0.01$0.03$0.07$0.09
Surprise %------------0.89%0.56%0.45%0.81%0.96%1.05%1.16%1.33%0.59%0.78%2.21%3.30%1.71%0.92%-3.99%-0.11%-0.54%

According to 4 Wall Street analysts, STAAR Surgical Company's projected average Quarter EPS for Mar 24 is $0.06, with a low estimate of $0.06 and a high estimate of $0.06. This represents a -61.72% decrease compared to STAA previous annual EPS of $0.16 (Dec 23).

STAAR Surgical Company Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
COOCooper Companies$104.86$298.00184.19%Buy
ANGOAngioDynamics$6.74$15.00122.55%Buy
STAASTAAR Surgical Company$29.14$54.5887.30%Buy
HAEHaemonetics$73.53$104.3341.89%Buy
RGENRepligen$139.53$189.5035.81%Buy
BDXBecton, Dickinson and Company$234.33$283.2720.89%Buy
WSTWest Pharmaceutical Services$314.77$345.339.71%Buy
NVSTEnvista$21.28$23.138.69%Hold
MMSIMerit Medical Systems$99.08$100.781.72%Buy
ICUIICU Medical$172.00$172.00-Buy
HOLXHologic$83.72$80.43-3.93%Buy
RMDResMed$243.61$219.13-10.05%Hold
ATRAptarGroup$168.26$138.00-17.98%Buy

STAA Forecast FAQ


Yes, according to 13 Wall Street analysts, STAAR Surgical Company (STAA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 84.62% of STAA's total ratings.

STAAR Surgical Company (STAA) average price target is $54.58 with a range of $45.03 to $85, implying a 87.30% from its last price of $29.14. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for STAA stock, the company can go up by 87.30% (from the last price of $29.14 to the average price target of $54.58), up by 191.70% based on the highest stock price target, and up by 54.53% based on the lowest stock price target.

STAA's average twelve months analyst stock price target of $54.58 supports the claim that STAAR Surgical Company can reach $40 in the near future.

STAAR Surgical Company's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $382.42M (high $399.77M, low $361.9M), average EBITDA is $46.98M (high $49.11M, low $44.46M), average net income is $44.65M (high $50.04M, low $38.99M), average SG&A $193.75M (high $202.54M, low $183.36M), and average EPS is $0.898 (high $1.01, low $0.784). STAA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $512.49M (high $534.76M, low $484.46M), average EBITDA is $62.96M (high $65.7M, low $59.52M), average net income is $46.25M (high $48.86M, low $42.96M), average SG&A $259.65M (high $270.93M, low $245.45M), and average EPS is $0.93 (high $0.983, low $0.864).

Based on STAAR Surgical Company's last annual report (Dec 2023), the company's revenue was $322.42K, which missed the average analysts forecast of $315.05M by -99.90%. Apple's EBITDA was $28.1K, missing the average prediction of $38.71M by -99.93%. The company's net income was $21.35K, missing the average estimation of $106.95M by -99.98%. Apple's SG&A was $224.55K, missing the average forecast of $159.62M by -99.86%. Lastly, the company's EPS was $0.43, missing the average prediction of $0.716 by -39.92%. In terms of the last quarterly report (Dec 2023), STAAR Surgical Company's revenue was $76.27K, missing the average analysts' forecast of $75.94M by -99.90%. The company's EBITDA was $10.4K, missing the average prediction of $9.33M by -99.89%. STAAR Surgical Company's net income was $7.76K, missing the average estimation of $8.89M by -99.91%. The company's SG&A was $50.32K, missing the average forecast of $38.48M by -99.87%. Lastly, the company's EPS was $0.16, missing the average prediction of $0.179 by -10.51%